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INTRODUCTION
Limb girdle muscular dystrophies (LGMDs) are a clinically
and genetically heterogeneous group of disorders, character-
ized by progressive weakness of proximal limb girdle mus-
cles. To date, at least seven different forms of autosomal domi-
nantly-inherited LGMD (LGMD1) have been recognized,
and 11 in cases of autosomal recessively-inherited ones (LG-
MD2). LGMD2A (MIM# 253600) consists of 30-60% of
all LGMD, and is assumed to be a major form among several
ethnic groups (1-7). It is caused by single or small nucleotide
changes distributed throughout a gene, named CAPN3 (MIM#
114240), which encodes the calpain 3 protein (8).
Calpains or calcium-activated neutral proteases are non-
lysosomal intracellular cysteine proteases. The mammalian
calpains include two ubiquitous proteins, calpain 1 (MIM#
114220) and calpain 2 (MIM# 114230), as well as two stom-
ach-specific proteins, and calpain 3, which is muscle-specif-
ic. Unlike dysferlin and sarcoglycans, which are involved in
LGMD2B and LGMD2C through 2F, respectively, calpain
3 is not a structural protein and disappears very rapidly in
vitro due to autolysis (9), frustrating immunohistochemical
staining popular in other muscular dystrophies. The human
CAPN3 covers a genomic region of more than 40 kb and is
composed of 24 exons. It is expressed predominantly in the
skeletal muscle tissue as a 3.5 kb transcript, driving the transla-
tion of a 94 kD protein. 
LGMD2A and the mutations in CAPN3 have not been
studied in the Korean population, although it is expected to
account for a large proportion of LGMD considering 26%
in the Japanese population (6). Here we first report the results
of mutational analysis of LGMD2A screened from Korean
LGMD patients.
MATERIALS AND METHODS
Selection of the subjects
We selected 35 patients registered in our clinic from 2000
to 2004 with the clinical diagnosis of LGMD, who satisfied
the following conditions: slowly progressive mild to moder-
ate limb girdle weakness and elevated serum creatine kinase
(CK) level, and various degrees of dystrophic changes on mus-
cle biopsy. The age distribution was in the range of 12-56 yr
old. Immunohistochemical stainings for dystrophin, merosin,
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Mutations of CAPN3 in Korean Patients with Limb-Girdle Muscular
Dystrophy
The limb-girdle muscular dystrophy type 2A (LGMD2A) is a recessively inherited
disease caused by a mutation of the calpain 3 gene (CAPN3), and is considered
one of the most prevalent subtypes of limb-girdle muscular dystrophy (LGMD). In
this study, we aimed to identify CAPN3 mutations and to characterize the pheno-
type of Korean patients with LGMD2A. Among 35 patients with LGMD, four patients,
who showed calpain 3 deficiency on western blot analysis, were analyzed in this
study. Total RNA extracted from frozen muscle tissue was amplified by reverse
transcriptase polymerase chain reaction (RT-PCR) using six primer pairs covering
all coding sequences of CAPN3, and direct sequencing was performed. Clinical
and pathological features of the patients were also reviewed. We found four differ-
ent mutations in five alleles from three patients. Of the pathogenic mutations iden-
tified, two were novel (c.2125T>C and c.2355-2357delTTC), and the others had
been reported elsewhere (c.440G>C, c.1076C>T). All patients showed a high CK
level with predominant proximal leg weakness, and the onset was in their childhood
except for one patient. Among two novel CAPN3 mutations, one was a missense
mutation (c.2125T>C [p.709Ser>Pro]), and the other was a small in-frame deletion
causing omission of a single amino acid (c.2355-2357delTTC [p.786delPhe]). The
clinical features of our patients were generally compatible with the characteristics
of LGMD2A patients described in the previous studies. 
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dysferlin and sarcoglycans revealed one case of Duchenne mus-
cular dystrophy (DMD; MIM#310200) in carrier state, one
case of merosinopathy (MDC1A; MIM#607855), and seven
cases of dysferlinopathy (LGMD2B; MIM# 253601), leaving
26 patients to be studied with western blot analysis.
Western blot analysis 
In each patient, 10-20 pieces of 6  m-thick muscle cryo-
sections were obtained, homogenized in 60  L of sodium
dodecyl sulfate (SDS) sample buffer by sonication, and heat-
ed at 95℃ for 5 min. Two microliters from each sample was
loaded to 6% SDS-polyacrylamide gel, and electrophoresed
over 20 mA for 1 hr before transferred to polyvinylidene diflu-
oride (PVDF) membrane. The blot was labeled with three
kinds of primary antibodies each targeting different epitopes
of calpain 3 (Calp3c/11B3, Calp3c/11A2, Calp3d/2C4; Novo-
castra, U.K.) (10) followed by secondary antibody reaction
(Histofine Simple Stain Max Po, Japan) overnight and detec-
tion with ECL western blotting detection reagent (Amer-
sham Bioscience, Piscataway, U.S.A.). 
Western blotting for dysferlin was then performed on the
patients with defective signal on at least one kind of calpain
3 antibody, to exclude secondary calpain 3 deficiency due to
dysferlin deficiency (11). 
Mutational analysis
In the patients with defective calapin 3 on western blot
study, further analysis was performed by screening mutations
in CAPN3. The purpose and methods were explained in de-
tail and written informed consents were obtained prior to
the study using their RNA and DNA. In order to identify
mutations, RT-PCR of CAPN3 and direct sequence analysis
were performed. Six sets of primers described before (12) were
used to cover the entire coding sequence of CAPN3, split
into about 600 bp-segments. Each PCR product was direct-
ly sequenced using BigDye terminator cycle sequencing kit
(Applied Biosystems, Foster City, U.S.A.) and 3730xl DNA
analyzer (Applied Biosystems). The aberrant sequences detect-
ed by sequence analysis were first searched in the Leiden Open
Variation Database (13). For the two mutations not found
in the database, PCR-RFLP assay or direct sequencing was
performed on each 100 alleles from a normal Korean popula-
tion to exclude normal variation. For c.2125T>C (p.709Ser
>Pro), genomic DNA region was amplified with primers
CAPN3-ex20.a (5′ -GGGGATTTTGCTGTGTGCTGT-3′ )
and CAPN3-ex20.m (5′ -ATTCCTGCTCCCACCGTCTC-
3′ ) (8). The products were digested by restriction endonu-
clease Hha III (Takara Bio, Tokyo, Japan) for 2 hr in 37℃,
to make a pattern of 234 bp and 106 bp in wild type, in con-
trast to the bands of 234 bp and 53 bp in mutant. For c.2355-
2357delTTC (p.786delPhe), we could not find an appropri-
ate restriction endonuclease that we amplified exon 22 by
PCR using primers CAPN3-ex22.a (5′ -CACAGAGTGG-
CCGAGAGGCA-3′ ) and CAPN3-ex22.m (5′ -GGAGAT-
TATCAGGTGAGATGCC-3′ ) (8), and performed direct
sequencing.
Clinical analysis of patients with calpain 3 deficiency
The clinical features of the patients, who showed calpain
3 deficiency on western blot analysis, were reviewed retro-
spectively based on their clinical records. The clinical histo-
ry was obtained from each patient in detail with the special
interest on the age at onset, first clinical symptom, the speed
of progression, current disabling problems, and family his-
tory. For clinical examination, presence of muscle atrophy or
hypertrophy, and associated musculoskeletal deformities were
carefully inspected. We examined changes in their tendon
reflexes and individual muscle power according to the Med-
ical Research Council (MRC) grade at first presentation, and
at certain points during clinical follow-up. The laboratory
tests including complete blood count, liver and renal func-
tion tests, thyroid function test, chest radiography, electrocar-
diogram (ECG), serum electrolytes, and serum creatine kinase
(CK) level were done in each patient. Muscle biopsies were
obtained from biceps muscles by open biopsy, and were pro-
cessed for routine histochemistry and reviewed for the diag-
nosis of muscular dystrophy. 
RESULTS
Western blot analysis
Four patients were found to show defective signal with at
least one primary antibody. Antibody Calp3c/11B3 was the
most sensitive showing defective calpain 3 band in all four
patients, while antibody Calp3c/12A2 showed defective bands
in patient 1 and 4, and antibody Calp3c/2C4 only in patient
4 (Fig. 1). No patient with deficient calpain 3 was associated
with dysferlin deficiency, supporting the evidence that all of
them are primarily deficient for calpain 3. None of the others
were deficient for either calpain 3 or dysferlin.
Mutation analysis
By direct sequencing of the CAPN3 mRNA amplified by
RT-PCR, five different mutations were identified among the
eight alleles, which are summarized in Table 1. We could
find only one mutation in cDNA from patient 1 and none
from patient 3. Patient 2 showed homozygous mutations.
Of the pathogenic mutations identified, the missense muta-
tion c.2125T>C (p.709Ser>Pro) from patient 1 (Fig. 2A) and
the in-frame deletion c.2355-2357delTTC (p.786delPhe)
from patient 4 (Fig. 2B) were novel, and no same change was
observed among 100 control alleles using PCR-RFLP andCAPN3 mutations in LGMD 465
the direct sequence analysis technique. Two other mutations
(c.440G>C, c.1076C>T) had been reported elsewhere (6, 14). 
Clinical features of the patients with calpain 3 deficiency
Patient 1, in whom we found a missense mutation (c.2125T
>C [p.709Ser>Pro]) in one allele, was 19 yr old at the time
of her first presentation to us. She developed difficulty in
climbing upstairs and leg pain at age 12, which slowly pro-
gressed to running difficulty at age 15. At presentation, she
could not lift up heavy objects or go upstairs without using
handrails. Although she did not show waddling gait, a clear
self-climbing motion was observed when she was asked to
stand up from squatting posture. Neither calf pseudohyper-
trophy nor muscle atrophy was evident. On muscle power
examination, she had MRC grade 3 weakness in leg eleva-
tion, and grade 4 in arm abduction, leg extension, leg adduc-
tion, leg abduction, knee extension, and knee flexion. The
deep tendon reflexes were hypoactive symmetrically in limbs.
She had no family history of similarly affected persons. Her
serum CK level was elevated to 1,275 IU/L (normal; 5-275
IU/L), and other laboratory tests including ECG and chest
radiography were unremarkable. Muscle biopsy showed mark-
ed muscle fiber size variation, increased connective tissue,
clusters of regenerating fibers, and scattered whirled fibers
with fiber splitting (Fig. 3A).
Patient 2, who had a homozygous missense mutation
(c.1076C>T [p.359Pro>Leu]) at exon 8, was a 47-yr-old
female at the time of her muscle biopsy. At her age of 30,
she first noticed difficulty in climbing stairs, which progre-
ssed to limitations in daily activities by age 44. At presenta-
tion, she had difficulty in rising up from chair and could not
stand up by herself from sitting position. Her muscle power
was reduced to MRC grade 1 in leg adduction, grade 2 in hip
flexion, hip extension, and leg abduction, grade 3 in shoul-
der elevation, elbow flexion, knee flexion and knee extension,
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Fig. 1. Western blot analysis of patient 1 (lane 5 of left column panels), patient 2 (lane 3 of middle column panels), and patient 3 and 4 (lane
2 and 4 of right column panels, respectively). Arrows indicate the presence of a band at the appropriate position, and asterisks (*) indicate
the absence. The lanes other than described above are from the other samples that have been found to be negative for calpainopathy.
*Novel mutations.
Mutation
cDNA 
Patient 
number Protein Location Type
Antibodies defective on 
western blot
1 c.2125T>C* p.709Ser>Pro Exon 20 Missense Calp3c/11B3, Calp3c/12A2
Otherwise unidentified
2 c.1076C>T, homozygous p.359Pro>Leu Exon 8 Missense Calp3c/11B3
3 Unidentified - - - Calp3c/11B3, Calp3d/2C4,
Calp3c/12A2
4 c.440G>C p.147Arg>Pro Exon 3 Missense Calp3c/11B3
c.2355-2357delTTC* p.786delPhe Exon 22 Small deletion 
Table 1. CAPN3 mutations identified in the study
Patient 3 (lane 2)
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Fig. 2. Mutations identified in the study. (A) Heterozygous c.2125T>C in patient 1 (arrow). Original amino acid serine has been changed into
proline by the mutation. (B) c.2355-2357delTTC in patient 4 (open arrow). Mutated allele misses the codon for phenylalanine. (C) Homozygous
c.1076C>T in patient 2 (arrow) changes the codon for amino acid proline into leucine. (D) Heterozygous c.440G>C in patient 4 (arrow)
changes codon for amino acid arginine into proline.
A
Asp
G A T A C A G A T GGC N C T GGAA AG C T C
(T/C)
Thr Asp Gly Pro Gly Lys Leu
C
Arg Leu Arg Asn Leu Cys Gly Gln Val
CGGCTGCGGAAT CTG TGGGGCCAGGTG
C
D
Gln Gln Leu Leu Phe Pro Val Ile Pro His Asp
CAG CA CC TT C TTTTCCN AG TCA TA CCCCA TG A T
(C/G)
B
Phe
Val Arg Leu Glu
TT C A T C T GC T G C TTC G TT A GGC T G
G TTA GG C T GG A G
del TTC
Ile Cys Cys Phe Val Arg Leu
Fig. 3. Muscle biopsy findings of the patients. (A) In patient 1, markedly increased contents of connective tissue and clusters of regenerat-
ing muscle fibers are observed. Hematoxylin and eosin (H&E) stain. (B) Marked muscle fiber size variation with many hypertrophic fibers,
and markedly increased contents of connective tissue are seen in muscle biopsy from patient 2. H&E stain. (C) In patient 2, type 1 fiber
predominance is also observed. ATPase stain at pH 4.3. (D) In patient 3, marked muscle fiber size variation, markedly increased contents
of connective tissue, and many fibers with rimmed vacuoles are seen. Modified Gomori-trichrome stain. Size of the bar=100  m.
A B
C Dand grade 4 in elbow extension and wrist flexion. Her deep
tendon reflexes were lost in limbs except for the ankle jerks.
She had no affected family members, and her serum CK level
was mildly elevated (496 IU/L). The ECG and chest radiog-
raphy were normal. Muscle biopsy showed a marked fiber
size variation, markedly increased adipose connective tissue,
many fibers with internal nuclei, scattered necrotic and regen-
erating fibers, some fibers undergoing fiber splitting, and
type I fiber predominance (Fig. 3B, C).
The patient 3 had been wheelchair-bound for one year when
he first presented to us at age 35. He became symptomatic
with gait and running difficulty when he was 13 yr old. Since
then, his disease was progressively worsened. He started to
use canes at age 32 and became wheelchair-bound at age 34.
He had a profound muscle weakness on examination. His
muscle power was graded as 1 in leg elevation, leg extension,
leg adduction, and leg abduction, 2 in distal leg muscles, 3
in upper extremity muscles, and 4 in quadriceps muscles.
He also had generalized muscle atrophy, especially in shoul-
der, pelvic girdle, and intrinsic hand muscles. His deep ten-
don reflexes were lost except for the knees. He had no affect-
ed family members, and serum CK was slightly elevated to
500 IU/L. His ECG and chest radiography were unremark-
able. Although he showed loss of immunoreactivity against
all the three sets of anti-calpain 3 antibodies, we were not
able to find any CAPN3 mutations. His muscle biopsy showed
a marked fiber size variation, markedly increased adipose con-
nective tissue, many fibers with internal nuclei, scattered
necrotic and regenerating fibers, many fibers with rimmed
vacuoles, and type I fiber predominance (Fig. 3D).
Patient 4, who was compound heterozygous for the muta-
tions c.440G>C (p.147Arg>Pro) and c.2355-2357delTTC
(p.786delPhe), was at her age of 21 when she first visited us
with progressive difficulty in climbing stairs and rising from
chairs. She became symptomatic when she was 8 yr old with
running difficulty and tiptoe gait. The tenorrhaphy had been
repeatedly performed due to progressive Achilles contracture.
At present, she has gait disturbance with waddling, difficulty
in climbing stairs and rising from chairs. Her muscle power
was significantly reduced to MRC grade 1 in leg adduction
and grade 2 in leg elevation. Muscles in proximal upper limbs
and all other lower limb muscles were less severely affected
and were graded as 4 to -4. She had a generalized areflexia.
Her familial history was significant for her brother and sister
who had the same problems with her. Her serum CK level
was elevated to 1,104 IU, and ECG and chest radiography
were normal. In muscle biopsy, there was a moderate fiber
size variation, mildly increased adipose connective tissue, and
a few regenerating fibers.
DISCUSSION
This is the first attempt to analyze the CAPN3 mutations
among Korean LGMD patients. We identified four patients
with calpain 3 deficiency by western blot analysis, and finally
found four different mutations including two novel ones. One
of our new mutation, c.2125T>C, changes a codon for polar
amino acid serine into nonpolar proline, which is likely to
produce a conformational change in the protein structure of
calpain 3. Another new mutation c.2355-2357delTTC pro-
duces a deletion of single amino acid phenylalanine at codon
786. In multiple alignment analysis, both mutations are locat-
ed in highly conserved regions of amino acid sequences across
several species (Fig. 4), strongly supporting that they are
pathogenic mutations. It is also remarkable that c.440G>C
mutation had been previously reported in a Japanese popu-
lation, which is known to be in close ethnic proximity with
the Korean population.
In contrast to other reports (1-7), we could find just a small
number of patients with CAPN3 mutations from a LGMD
patient pool. This is thought to be partly because we could
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Fig. 4. Multiple alignment analysis of amino acid sequences of calpain 3 in different species. Both mutated amino acids serine (S, marked
in panel A) and phenylalanine (F, marked in panel B) are highly conserved across several species. H. sapiens: human, M. mulatta: rhesus
monkey, M. musculus: house mouse, R. norvegicus: Norway rat, G. gallus: chicken, C. familaris: dog.not reliably exclude autosomal dominant cases, but also that
we have screened the patients first by western blot analysis.
Although western blot analysis is still considered as a stan-
dard tool for the screening of LGMD2A, it seems neither
perfectly sensitive nor specific (10, 15-17). According to a
study employing a large number of genetically confirmed
LGMD2A patients, the diagnostic sensitivity and specificity
of western blot analysis were estimated as 52.5% and 87.8%,
respectively (17). In our study, we used three types of west-
ern blot antibodies in order to maximize the sensitivity, but
the antibody Calp3c/11B3 was found to be the most useful,
which is known to have the widest reaction profile, binding
other calpain molecules even from other species (10). Direct
sequencing of the CAPN3 gene cannot detect all the muta-
tions either, as exemplified by our case, that the two tech-
niques are complementary. It is contradictory that patient 3
in whom we could not find any pathologic mutation, show-
ed the clearest pattern of calpain 3 abnormality on western
blot. Overall, we have failed to detect mutations in three alle-
les. As we have sequenced CAPN3 by RT-PCR, each segment
spanning about 600 bp, a large deletion involving primer
site could be the cause, although such mutation has not been
reported so far. Mutations may be in the regulatory region,
affecting the transcriptional activity, which has not been re-
ported either.
The clinical features of LGMD2A had been studied and
characterized in a few previous studies, and following features
are now considered as typical: onset between 8-16 yr, early
symmetrical weakness of proximal legs, no facial or cardiac
involvement, normal intelligence, wheelchair-bound between
20 to 40 yr old, no muscle contracture except for the Achilles
tendon, hyporeflexia, and a 5-20 fold increase in the CK level
(16, 17, 19, 20). The clinical features of our patients are con-
sidered to be typical for LGMD2A. All of our patients showed
a high CK level ranging 496-1,275 U/L. The weakness was
predominant in their lower extremities, the onset was from
childhood except for patient 2, deep tendon reflexes were lost
or reduced, and none had mental or cardiac abnormalities. 
Although LGMD2A is supposed to account for a major
proportion in LGMD, it has been neglected in the Korean
populations, partly due to the costly diagnostic procedure.
Further studies using a larger number of patients with LG-
MD2A are needed to fully elucidate the genotypic and clin-
ical characteristics of Korean patients with LGMD2A.
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